US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000042072A2
(en)
|
1999-01-15 |
2000-07-20 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
DE60142614D1
(de)
*
|
2000-01-27 |
2010-09-02 |
Medimmune Inc |
Inität
|
DK1259547T3
(da)
*
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP2341060B1
(de)
*
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
US7658921B2
(en)
*
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
JP4585968B2
(ja)
*
|
2002-05-10 |
2010-11-24 |
パーデュー・リサーチ・ファウンデーション |
EphA2アゴニストモノクローナル抗体およびその使用法
|
US20050152899A1
(en)
*
|
2002-05-10 |
2005-07-14 |
Kinch Michael S. |
EphA2 agonistic monoclonal antibodies and methods of use thereof
|
US20040028685A1
(en)
*
|
2002-05-10 |
2004-02-12 |
Kinch Michael S. |
EphA2 monoclonal antibodies and methods of use thereof
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
*
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
CA2502904C
(en)
*
|
2002-10-15 |
2013-05-28 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
*
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
*
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP2272533A1
(de)
|
2003-01-13 |
2011-01-12 |
MacroGenics, Inc. |
Lösliche FcyR-Fusionsproteine und Verfahren zu deren Verwendung
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP4685764B2
(ja)
*
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
EP1617864A4
(de)
*
|
2003-04-11 |
2006-06-21 |
Medimmune Inc |
Epha2 und nicht-neoplastische hyperproliferative zellstörungen
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2005003175A2
(en)
*
|
2003-06-13 |
2005-01-13 |
Biogen Idec Ma Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
JP4178514B2
(ja)
*
|
2003-06-27 |
2008-11-12 |
東洋紡績株式会社 |
抗体のスクリーニング方法
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
CA2536408A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
EP3192872A1
(de)
*
|
2003-08-26 |
2017-07-19 |
The Regents of the University of Colorado, a body corporate |
Inhibitoren der serinproteaseaktivität und deren verwendung in verfahren und zusammensetzungen zur behandlung bakterieller infektionen
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
AU2005227326B2
(en)
*
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
EP1755673B1
(de)
|
2004-04-12 |
2014-07-23 |
MedImmune, LLC |
Anti-il-9-antikörperformulierungen und deren verwendung
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
KR20070047327A
(ko)
|
2004-07-26 |
2007-05-04 |
비오겐 아이덱 엠에이 아이엔씨. |
항-cd154 항체
|
EP2213683B1
(de)
|
2004-08-04 |
2013-06-05 |
Mentrik Biotech, LLC |
Varianten der Fc Regionen
|
CA2577329A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Inc. |
Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
AU2005285347A1
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
EP1812068A4
(de)
*
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK2325207T3
(en)
*
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
DE602006005200D1
(de)
|
2005-01-05 |
2009-04-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
EP1858925A2
(de)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antikörper und fc-fusionsproteine mit veränderter immunogenizität
|
WO2006079120A2
(en)
*
|
2005-01-24 |
2006-07-27 |
Board Of Regents, The University Of Texas System |
Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
US8999943B2
(en)
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
US7531637B2
(en)
|
2005-05-06 |
2009-05-12 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
US8309690B2
(en)
*
|
2005-07-01 |
2012-11-13 |
Medimmune, Llc |
Integrated approach for generating multidomain protein therapeutics
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
CA2624189A1
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
*
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
US7709456B2
(en)
|
2005-11-17 |
2010-05-04 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
CA2631184A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
EP2567973B1
(de)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21-Antagonisten
|
ES2388932T3
(es)
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
AU2007212147A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
EP2540741A1
(de)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
WO2007114325A1
(ja)
*
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
EP4001409A1
(de)
*
|
2006-03-31 |
2022-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blutkinetik eines antikörpers
|
RS53168B
(en)
|
2006-05-30 |
2014-06-30 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
EP2032159B1
(de)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
|
EP2505209A1
(de)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
CN103524619B
(zh)
|
2006-08-03 |
2016-10-05 |
阿斯利康(瑞典)有限公司 |
针对αVβ6的抗体及其应用
|
ES2613957T3
(es)
|
2006-08-04 |
2017-05-29 |
Medimmune Limited |
Anticuerpos contra ERBB2
|
ES2457072T3
(es)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
ES2519375T3
(es)
|
2006-09-01 |
2014-11-06 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y procedimientos de uso
|
DK2066349T3
(da)
|
2006-09-08 |
2012-07-09 |
Medimmune Llc |
Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
EP2064335A4
(de)
*
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
RS53942B1
(en)
|
2006-10-27 |
2015-08-31 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
BRPI0720552A2
(pt)
|
2006-12-19 |
2014-01-07 |
Genentech Inc |
Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
|
WO2008112192A2
(en)
|
2007-03-08 |
2008-09-18 |
Kalobios Pharmaceuticals, Inc. |
Epha3 antibodies for the treatment of solid tumors
|
EP1980269A1
(de)
*
|
2007-04-13 |
2008-10-15 |
Katholieke Universiteit Leuven |
Prävention von Staphylokokken-Biofilmbildung
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
CN101802006B
(zh)
|
2007-06-26 |
2013-08-14 |
F-星生物技术研究与开发有限公司 |
展示结合剂
|
US20110077383A1
(en)
*
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
AU2008290539B2
(en)
*
|
2007-08-21 |
2013-07-25 |
Morphosys Ag |
Improved methods for the formation of disulphide bonds
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
MX342551B
(es)
|
2007-09-26 |
2016-10-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
JP5767475B2
(ja)
|
2007-11-05 |
2015-08-19 |
メディミューン,エルエルシー |
強皮症の治療方法
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
BRPI0821168B8
(pt)
|
2007-12-07 |
2021-05-25 |
Zymogenetics Inc |
anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
|
BRPI0820099A2
(pt)
|
2007-12-07 |
2020-11-24 |
Zymogenetics, Inc |
anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
EP4098661A1
(de)
*
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc-varianten mit veränderter bindung an fcrn
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
EP2080770A1
(de)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinöse Bindemoleküle mit Reinigungstags
|
AU2009212273B2
(en)
|
2008-02-08 |
2014-07-31 |
Astrazeneca Ab |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
MX2010010387A
(es)
|
2008-04-02 |
2010-10-15 |
Macrogenics Inc |
Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
|
DK2247304T3
(en)
|
2008-04-02 |
2016-09-26 |
Macrogenics Inc |
Her2 / neu-specific antibodies and methods of use thereof
|
NZ602884A
(en)
|
2008-04-11 |
2014-08-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
WO2009129538A2
(en)
*
|
2008-04-18 |
2009-10-22 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
US20100021460A1
(en)
*
|
2008-07-15 |
2010-01-28 |
Genentech, Inc. |
Methods of Treating Autoimmune Diseases Using CD4 Antibodies
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
CN110317272A
(zh)
*
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
HUE032693T2
(en)
|
2008-11-22 |
2017-10-30 |
Hoffmann La Roche |
Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010088444A1
(en)
*
|
2009-01-29 |
2010-08-05 |
Medimmune, Llc |
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
|
CA2753995A1
(en)
|
2009-03-06 |
2010-09-10 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
DK2406399T3
(en)
|
2009-03-09 |
2018-03-12 |
Bioatla Llc |
MIRAC PROTEINS
|
BRPI1009460A2
(pt)
|
2009-03-16 |
2016-03-01 |
Cephalon Australia Pty Ltd |
domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP2233500A1
(de)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimierte Fc Varianten
|
CN102378767B
(zh)
|
2009-03-25 |
2015-01-14 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
EA030182B1
(ru)
|
2009-04-20 |
2018-07-31 |
Оксфорд Байотерепьютикс Лтд. |
Антитела, специфические для кадгерина-17
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법
|
EP3381937A3
(de)
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Verfahren zur modulierung der immunfunktion
|
TW201431558A
(zh)
|
2009-08-15 |
2014-08-16 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
CA2772051C
(en)
|
2009-08-24 |
2020-08-18 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
EP2481752B1
(de)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modifizierte konstante antikörperregionen
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2486141B1
(de)
|
2009-10-07 |
2018-01-10 |
MacroGenics, Inc. |
Fc-regionshaltige polypeptide mit besserer effektorfunktion aufgrund von änderungen des ausmasses einer fukosylierung sowie verwendungsverfahren dafür
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
PL2488554T3
(pl)
|
2009-10-14 |
2020-03-31 |
Humanigen, Inc. |
Przeciwciała przeciw epha3
|
KR20120105447A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
항-헵신 항체 및 그의 사용 방법
|
WO2011053982A2
(en)
|
2009-11-02 |
2011-05-05 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
JP6007420B2
(ja)
|
2009-11-04 |
2016-10-12 |
ファブラス エルエルシー |
親和性成熟に基づく抗体最適化方法
|
ES2636971T3
(es)
|
2009-11-05 |
2017-10-10 |
F. Hoffmann-La Roche Ag |
Procedimientos y composición para la secreción de polipéptidos heterógenos
|
EP2496257A4
(de)
|
2009-11-05 |
2013-02-27 |
Cephalon Australia Pty Ltd |
Behandlung von krebs mit mutierten kras- oder braf-genen
|
US8881354B2
(en)
|
2009-11-16 |
2014-11-11 |
Jtekt Corporation |
Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
HUE028629T2
(en)
|
2009-12-23 |
2016-12-28 |
Synimmune Gmbh |
Anti-FLT3 antibodies and ways of their use
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
ES2561102T3
(es)
|
2010-01-13 |
2016-02-24 |
Oncomed Pharmaceuticals, Inc. |
Agentes de unión a Notch1 y procedimientos de uso de los mismos
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
WO2011102845A1
(en)
*
|
2010-02-18 |
2011-08-25 |
Transtech Pharma, Inc. |
Rage fusion protein compositions and methods of use
|
KR20180028561A
(ko)
|
2010-02-23 |
2018-03-16 |
제넨테크, 인크. |
난소암의 치료를 위한 항혈관신생 요법
|
KR101510932B1
(ko)
|
2010-02-25 |
2015-04-10 |
아사히 가세이 이-매터리얼즈 가부시키가이샤 |
산화구리용 에칭액 및 그것을 이용한 에칭 방법
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
NZ705128A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
PL2563813T3
(pl)
|
2010-04-30 |
2016-01-29 |
Alexion Pharma Inc |
Przeciwciała anty-C5a i sposoby stosowania przeciwciał
|
JP5956982B2
(ja)
|
2010-05-27 |
2016-07-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
改善された特性を有する抗体の製造方法
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CA2800913C
(en)
|
2010-06-03 |
2019-07-23 |
Pharmacyclics, Inc. |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
AU2011261362B2
(en)
|
2010-06-03 |
2016-06-09 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
TWI627964B
(zh)
|
2010-07-09 |
2018-07-01 |
傑森疫苗防護公司 |
抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
JP5972871B2
(ja)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗il−23ヘテロ二量体特異的抗体
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
DK2598526T3
(en)
|
2010-07-29 |
2018-11-19 |
Eleven Biotherapeutics Inc |
CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
|
EP2601216B1
(de)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
AU2011288412A1
(en)
|
2010-08-13 |
2013-02-21 |
Medimmune Limited |
Monomeric polypeptides comprising variant Fc regions and methods of use
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
SG187965A1
(en)
|
2010-08-27 |
2013-04-30 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
WO2012045085A1
(en)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
EA031044B1
(ru)
|
2010-10-13 |
2018-11-30 |
Янссен Байотек, Инк. |
Человеческие антитела к онкостатину м и способы их применения
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
PT2644698T
(pt)
|
2010-11-17 |
2018-01-31 |
Chugai Pharmaceutical Co Ltd |
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
|
LT2643352T
(lt)
|
2010-11-23 |
2018-08-10 |
Glaxo Group Limited |
Antigeną onkostatiną m (osm) surišantys baltymai
|
KR20130121886A
(ko)
|
2010-11-24 |
2013-11-06 |
글락소 그룹 리미티드 |
Hgf를 표적으로 하는 다중특이적 항원 결합 단백질
|
CN103429737B
(zh)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
KR102385507B1
(ko)
|
2010-11-30 |
2022-04-12 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
CN106279415A
(zh)
|
2010-12-08 |
2017-01-04 |
施特姆森特克斯股份有限公司 |
新型调节子及使用方法
|
ES2720136T3
(es)
|
2010-12-22 |
2019-07-18 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpo modificado con semivida mejorada
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CN103443285B9
(zh)
|
2011-02-08 |
2018-04-24 |
米迪缪尼有限公司 |
特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
MX354359B
(es)
|
2011-03-29 |
2018-02-28 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
BR112013026423A2
(pt)
|
2011-04-20 |
2016-11-29 |
Roche Glycart Ag |
método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
|
US10654916B2
(en)
|
2011-04-21 |
2020-05-19 |
The Regents Of The University Of California, A California Corporation |
Compositions and methods for the treatment of neuromyelitis optica
|
SI2704737T1
(en)
|
2011-04-29 |
2018-06-29 |
University Of Washington |
Therapeutic nucleosomal compositions and procedures
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
CA2834589A1
(en)
|
2011-05-25 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Method for preparing fc-containing polypeptides having improved properties
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
KR102111171B1
(ko)
|
2011-06-10 |
2020-05-14 |
메디뮨 엘엘씨 |
항슈도모나스 psl 결합 분자 및 그의 용도
|
MX343580B
(es)
|
2011-06-13 |
2016-11-10 |
Csl Ltd |
Anticuerpos contra el g-csfr y sus usos.
|
KR102103476B1
(ko)
|
2011-06-24 |
2020-04-23 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
|
JP6247209B2
(ja)
|
2011-06-28 |
2017-12-13 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Adpリボシルシクラーゼ2に対する抗体
|
WO2013003641A2
(en)
*
|
2011-06-28 |
2013-01-03 |
Inhibrx Llc |
Serpin fusion polypeptides and methods of use thereof
|
US8986688B2
(en)
*
|
2011-06-28 |
2015-03-24 |
Inhibrx, Llc |
WAP domain fusion polypeptides and methods of use thereof
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
AU2012284254B2
(en)
|
2011-07-15 |
2015-07-09 |
Oncomed Pharmaceuticals, Inc. |
RSPO binding agents and uses thereof
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
IL230564B2
(en)
|
2011-07-22 |
2023-09-01 |
Csl Ltd |
Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
|
EP2548892A1
(de)
|
2011-07-22 |
2013-01-23 |
CSL Behring GmbH |
Inhibitorische Antikörper gegen Factor XII/XIIa und ihre Verwendungen
|
CN103842380A
(zh)
|
2011-07-27 |
2014-06-04 |
葛兰素集团有限公司 |
融合至Fc结构域的抗VEGF单可变结构域
|
SG10201606218WA
(en)
|
2011-07-29 |
2016-09-29 |
Eleven Biotherapeutics Inc |
Purified Proteins
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
MX361712B
(es)
|
2011-09-23 |
2018-12-14 |
Oncomed Pharm Inc |
Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dell4) y usos de los mismos.
|
US20140335089A1
(en)
|
2011-09-30 |
2014-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
CN104114577A
(zh)
|
2011-09-30 |
2014-10-22 |
特瓦制药澳大利亚私人有限公司 |
针对TL1a的抗体及其用途
|
CA2850322C
(en)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
US20150299313A1
(en)
|
2011-10-05 |
2015-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
|
SI2771022T1
(sl)
|
2011-10-11 |
2020-12-31 |
Viela Bio, Inc. |
CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe
|
CN107233569B
(zh)
|
2011-10-25 |
2021-08-31 |
普罗西纳生物科学有限公司 |
抗体制剂和方法
|
BR112014009925B1
(pt)
|
2011-10-28 |
2022-09-20 |
Teva Pharmaceuticals Australia Pty Ltd |
Construtores de polipeptídeos e seus usos
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
EP2773664A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
AU2012332587B2
(en)
|
2011-11-01 |
2017-02-23 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
PL2776065T3
(pl)
|
2011-11-07 |
2020-12-14 |
Medimmune Limited |
Terapie skojarzone z zastosowaniem cząsteczek wiążących przeciwko psl i pcrv pseudomonas
|
US9580509B2
(en)
|
2011-11-07 |
2017-02-28 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
US20140302028A1
(en)
*
|
2011-11-18 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
|
EP3608340A1
(de)
|
2011-11-23 |
2020-02-12 |
Medlmmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
KR20140100532A
(ko)
|
2011-11-30 |
2014-08-14 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
US9416179B2
(en)
|
2011-12-05 |
2016-08-16 |
X-Body, Inc. |
PDGF receptor beta binding polypeptides
|
US9527927B2
(en)
|
2011-12-20 |
2016-12-27 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
ES2751386T3
(es)
*
|
2011-12-21 |
2020-03-31 |
Amgen Inc |
Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
EP2793944A4
(de)
|
2011-12-23 |
2015-09-02 |
Nicholas B Lydon |
Immunoglobuline und varianten gegen pathogene mikroben
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Fc 단편 유도체
|
EP2802653A4
(de)
|
2012-01-10 |
2015-09-02 |
Univ Colorado Regents |
Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
|
HUE046396T2
(hu)
|
2012-01-12 |
2020-02-28 |
Bioverativ Therapeutics Inc |
Kiméra faktor VIII polipeptidek és ezek alkalmazása
|
EP2623110A1
(de)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen
|
JP6226752B2
(ja)
*
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のFc領域改変体
|
ES2935489T3
(es)
|
2012-02-15 |
2023-03-07 |
Bioverativ Therapeutics Inc |
Composiciones de factor VIII y métodos de preparación y uso de las mismas
|
KR102008190B1
(ko)
|
2012-02-15 |
2019-08-07 |
바이오버라티브 테라퓨틱스 인크. |
재조합 인자 viii 단백질
|
SG10201805584YA
(en)
|
2012-02-24 |
2018-08-30 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
|
SI2817338T1
(sl)
|
2012-02-24 |
2017-11-30 |
Abbvie Stemcentrx Llc |
Modulatorji DLL3 in postopki uporabe
|
UA117097C2
(uk)
|
2012-03-28 |
2018-06-25 |
Санофі |
Антитіло проти лігандів рецептора в1 брадикініну
|
US10385395B2
(en)
|
2012-04-11 |
2019-08-20 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
WO2013165690A1
(en)
*
|
2012-04-30 |
2013-11-07 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
CA2872856A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
US20130336973A1
(en)
|
2012-05-10 |
2013-12-19 |
Zymeworks Inc. |
Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
DK2857420T3
(da)
|
2012-05-30 |
2020-11-23 |
Chugai Pharmaceutical Co Ltd |
Målvævsspecifikt antigenbindende molekyle
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
EP3202419A1
(de)
|
2012-06-06 |
2017-08-09 |
OncoMed Pharmaceuticals, Inc. |
Pvrig bindungsmittel zur modulation des hippo-pfads und verwendungen davon
|
CN104427995A
(zh)
|
2012-06-08 |
2015-03-18 |
比奥根艾迪克Ma公司 |
嵌合凝血因子
|
AU2013270682A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Procoagulant compounds
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3404105A1
(de)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
JP6603128B2
(ja)
|
2012-07-11 |
2019-11-06 |
バイオベラティブ セラピューティクス インコーポレイテッド |
XTENおよびvonWillebrand因子タンパク質を有する第VIII因子の複合体、および、その使用
|
WO2014009465A1
(en)
|
2012-07-13 |
2014-01-16 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
BR112015001690A2
(pt)
|
2012-07-24 |
2017-11-07 |
Pharmacyclics Inc |
mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
|
BR112015001459B1
(pt)
|
2012-07-25 |
2023-02-14 |
Celldex Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
|
WO2014029752A1
(en)
|
2012-08-22 |
2014-02-27 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
RU2729831C2
(ru)
|
2012-08-24 |
2020-08-12 |
Чугаи Сейяку Кабусики Кайся |
ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
AU2013315499B2
(en)
|
2012-09-12 |
2018-08-09 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
EP2928483A4
(de)
|
2012-12-04 |
2016-06-08 |
Oncomed Pharm Inc |
Immuntherapie mit bindemitteln
|
BR112015014063A2
(pt)
|
2012-12-19 |
2018-10-30 |
Amplimmune Inc |
anticorpos anti-b7-h4 humano e seus usos.
|
EP2935332B1
(de)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antikörpern
|
KR20220156667A
(ko)
|
2013-01-10 |
2022-11-25 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
RU2015130100A
(ru)
|
2013-01-24 |
2017-03-03 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
TNF-альфа антиген-связывающие белки
|
CA2898121A1
(en)
|
2013-01-25 |
2014-07-31 |
Shire Human Genetic Therapies, Inc. |
Follistatin in treating duchenne muscular dystrophy
|
US9840559B2
(en)
|
2013-02-01 |
2017-12-12 |
The Regents Of The University Of California |
Anti-CD83 antibodies and use thereof
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路インヒビターによる処置の方法およびモニタリング
|
CN110551217B
(zh)
|
2013-02-07 |
2023-12-15 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
EP4223772A3
(de)
|
2013-02-15 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-viii-gen
|
DK2958944T3
(da)
|
2013-02-22 |
2019-06-24 |
Abbvie Stemcentrx Llc |
Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
ES2844189T3
(es)
|
2013-03-08 |
2021-07-21 |
Csl Behring Gmbh |
Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
|
KR102420934B1
(ko)
|
2013-03-11 |
2022-07-15 |
젠자임 코포레이션 |
과글리코실화된 결합 폴리펩티드
|
CN107693781B
(zh)
|
2013-03-13 |
2021-11-09 |
巴扎德制药公司 |
用于眼部递送的嵌合细胞因子制剂
|
AP2015008740A0
(en)
|
2013-03-14 |
2015-09-30 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
|
US20140271641A1
(en)
|
2013-03-14 |
2014-09-18 |
University Of Guelph |
Thrombospondin-1 polypeptides and methods of using same
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
PL2970464T3
(pl)
|
2013-03-15 |
2020-10-05 |
Glaxosmithkline Intellectual Property Development Limited |
Wiążące białka anty-lag-3
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
EP3460054B1
(de)
|
2013-03-15 |
2020-10-21 |
aTyr Pharma, Inc. |
Histidyl-trna-synthetase-fc-konjugate
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
BR112015023084A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
|
AU2014233503A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
AU2014236769B2
(en)
|
2013-03-15 |
2018-09-27 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
EP3783017A1
(de)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Varianten der fc-region
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
EA033115B1
(ru)
|
2013-04-29 |
2019-08-30 |
Тева Фармасьютикалз Острэйлиа Пти Лтд. |
АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
|
JP6612214B2
(ja)
|
2013-05-20 |
2019-11-27 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及び使用方法
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
TWI592426B
(zh)
|
2013-08-13 |
2017-07-21 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
US9845363B2
(en)
|
2013-08-13 |
2017-12-19 |
Sanofi |
Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
MX2016002574A
(es)
|
2013-08-28 |
2016-06-14 |
Stemcentrx Inc |
Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
|
MX2016002547A
(es)
|
2013-08-28 |
2016-06-17 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
HUE049281T2
(hu)
|
2013-09-13 |
2020-09-28 |
Beigene Switzerland Gmbh |
Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
|
EP3903599A1
(de)
|
2013-09-25 |
2021-11-03 |
Bioverativ Therapeutics Inc. |
Verfahren zur virusinaktivierung auf einer säule
|
EP3733710A1
(de)
|
2013-09-25 |
2020-11-04 |
Amgen, Inc |
Heterodimeriche v-c-fc-v-c-antikörper
|
SG11201602261VA
(en)
|
2013-09-27 |
2016-04-28 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
BR112016006999B1
(pt)
|
2013-10-02 |
2023-11-14 |
Medimmune, Llc |
Anticorpos neutralizantes antiinfluenza a seus usos, seu método de produção, composição que os compreendem, ácido nucleico e vetor
|
US10081682B2
(en)
|
2013-10-11 |
2018-09-25 |
Oxford Bio Therapeutics Ltd. |
Conjugated antibodies against LY75 for the treatment of cancer
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
SG11201603397QA
(en)
|
2013-11-06 |
2016-05-30 |
Stemcentrx Inc |
Novel anti-claudin antibodies and methods of use
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
EP3074039A4
(de)
*
|
2013-11-26 |
2017-10-11 |
The Brigham and Women's Hospital, Inc. |
Zusammensetzungen und verfahren zur modulierung einer immunreaktion
|
WO2015084808A1
(en)
|
2013-12-02 |
2015-06-11 |
Oncomed Pharmaceuticals, Inc. |
Identification of predictive biomarkers associated with wnt pathway inhibitors
|
MX2016007312A
(es)
|
2013-12-04 |
2017-01-13 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
|
CN114044825A
(zh)
|
2013-12-09 |
2022-02-15 |
爱乐科斯公司 |
抗Siglec-8抗体及其使用方法
|
EP2883883A1
(de)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
CN112142843A
(zh)
|
2013-12-24 |
2020-12-29 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
SG11201605242YA
(en)
|
2014-01-10 |
2016-07-28 |
Biogen Ma Inc |
Factor viii chimeric proteins and uses thereof
|
WO2015123687A1
(en)
|
2014-02-14 |
2015-08-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
DK3110446T3
(da)
|
2014-02-28 |
2022-02-28 |
Allakos Inc |
Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CN106103730B
(zh)
|
2014-03-14 |
2021-06-08 |
豪夫迈·罗氏有限公司 |
用于分泌异源多肽的方法和组合物
|
US9738702B2
(en)
*
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
SI3129067T1
(sl)
|
2014-03-19 |
2023-06-30 |
Genzyme Corporation |
Za mesto specifičen glikoinženiring tarčnih deležev
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
CN106164094B
(zh)
|
2014-03-21 |
2021-05-14 |
X博迪公司 |
双特异性抗原结合多肽
|
JP6614582B2
(ja)
|
2014-04-04 |
2019-12-04 |
バイオノミクス インコーポレイテッド |
Lgr5に結合するヒト化抗体
|
SG10201913627TA
(en)
|
2014-04-08 |
2020-03-30 |
Boston Pharmaceuticals Inc |
Binding molecules specific for il-21 and uses thereof
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
JP6832709B2
(ja)
*
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
US10155818B2
(en)
|
2014-05-28 |
2018-12-18 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
EP3155013B1
(de)
*
|
2014-06-12 |
2019-03-27 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl von antikörpern mit modifizierter fcrn-interaktion
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
WO2016000619A1
(en)
|
2014-07-03 |
2016-01-07 |
Beigene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
US10294292B2
(en)
|
2014-07-15 |
2019-05-21 |
Medimmune, Llc |
Neutralizing anti-influenza B antibodies and uses thereof
|
RU2711141C2
(ru)
|
2014-07-22 |
2020-01-15 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Антитела против pd-1
|
NZ728749A
(en)
|
2014-08-05 |
2023-06-30 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
WO2016025331A1
(en)
|
2014-08-11 |
2016-02-18 |
University Of Massachusetts |
Anti-ospa antibodies and methods of use
|
EA202193002A2
(ru)
|
2014-09-03 |
2022-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединение, нацеленное на ил-23a и фно-альфа, и его применение
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
JP2017529853A
(ja)
|
2014-09-25 |
2017-10-12 |
アムジエン・インコーポレーテツド |
プロテアーゼにより活性化可能な二重特異性タンパク質
|
SG11201701803XA
(en)
|
2014-09-26 |
2017-04-27 |
Bayer Pharma AG |
Stabilized adrenomedullin derivatives and use thereof
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
BR112017006515A8
(pt)
|
2014-09-29 |
2018-02-27 |
Univ Duke |
moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
|
WO2016050867A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune Limited |
Antibodies to ticagrelor and methods of use
|
AU2015330869B2
(en)
|
2014-10-09 |
2021-07-08 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
NZ731491A
(en)
|
2014-10-23 |
2021-12-24 |
Kira Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
CN107106656A
(zh)
|
2014-10-29 |
2017-08-29 |
梯瓦制药澳大利亚股份有限公司 |
干扰素α2b变体
|
US20160130324A1
(en)
|
2014-10-31 |
2016-05-12 |
Shire Human Genetic Therapies, Inc. |
C1 Inhibitor Fusion Proteins and Uses Thereof
|
BR112017008666A2
(pt)
|
2014-11-05 |
2018-01-30 |
Genentech, Inc. |
anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
|
CN107074966A
(zh)
*
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
|
GB2537445A
(en)
|
2014-11-10 |
2016-10-19 |
Medimmune Ltd |
Binding molecules specific for CD73 and uses thereof
|
JP6847037B2
(ja)
|
2014-11-11 |
2021-03-24 |
メディミューン リミテッド |
抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
|
EP3221361B1
(de)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
MX2017006323A
(es)
|
2014-11-21 |
2017-08-21 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
CN113773388A
(zh)
|
2014-11-21 |
2021-12-10 |
百时美施贵宝公司 |
抗cd73抗体及其用途
|
US9382321B2
(en)
|
2014-11-26 |
2016-07-05 |
Adventis Health System/Sunbelt, Inc. |
Effector-deficient anti-CD32A antibodies
|
KR20170085595A
(ko)
|
2014-12-10 |
2017-07-24 |
제넨테크, 인크. |
혈뇌 장벽 수용체 항체 및 사용 방법
|
SG11201700841QA
(en)
|
2014-12-19 |
2017-03-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
AU2015365167B2
(en)
|
2014-12-19 |
2021-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies and methods of use
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
KR102644115B1
(ko)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Tigit에 대한 항체
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
CN107428818A
(zh)
|
2015-01-29 |
2017-12-01 |
密西根州立大学校董会 |
隐藏多肽及其用途
|
CN114773469A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
JP6130983B2
(ja)
|
2015-02-27 |
2017-05-17 |
中外製薬株式会社 |
Il−6関連疾患治療用組成物
|
MY188761A
(en)
|
2015-03-09 |
2021-12-29 |
Argenx Bvba |
Method of reducing serum levels of fc-containing agents using fcrn antagonists
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
RS61438B1
(sr)
|
2015-03-31 |
2021-03-31 |
Medimmune Ltd |
Novi oblik il33, mutirani oblici il33, antitela, testovi i postupci za njihovu upotrebu
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
HUE061253T2
(hu)
|
2015-05-29 |
2023-06-28 |
Bristol Myers Squibb Co |
Antitestek OX40 ellen és azok felhasználásai
|
KR101978765B1
(ko)
|
2015-06-04 |
2019-05-15 |
오스페달레 산 라파엘 에스.알.엘. |
Igfbp3/tmem219 축 및 당뇨병의 저해제
|
US10682391B2
(en)
|
2015-06-04 |
2020-06-16 |
Ospedale San Raffaele Srl |
Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases
|
SG10201911349YA
(en)
*
|
2015-06-05 |
2020-01-30 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
WO2016205567A1
(en)
|
2015-06-17 |
2016-12-22 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
WO2017015433A2
(en)
|
2015-07-23 |
2017-01-26 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
|
KR20180093127A
(ko)
|
2015-07-30 |
2018-08-20 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
EA201890185A1
(ru)
|
2015-07-31 |
2018-07-31 |
Медиммун Лимитед |
Способы лечения опосредованных гепсидином нарушений
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
PE20181322A1
(es)
|
2015-09-01 |
2018-08-14 |
Agenus Inc |
Anticuerpo anti-pd1 y sus metodos de uso
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
CA2999160A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
SG11201801984TA
(en)
|
2015-10-01 |
2018-04-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
IL258521B2
(en)
|
2015-10-08 |
2024-01-01 |
Macrogenics Inc |
Combination of treatments for cancer treatment
|
RU2694903C1
(ru)
|
2015-10-12 |
2019-07-18 |
АПРОДЖЕН КейАйСи ИНК. |
Антитела к CD43 и их применение для лечения рака
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
RU2710194C9
(ru)
|
2015-11-10 |
2020-09-14 |
МЕДИММЬЮН, ЭлЭлСи |
Связывающие молекулы, специфичные в отношении asct2, и их применения
|
ES2810755T3
(es)
|
2015-11-30 |
2021-03-09 |
Abbvie Inc |
Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
|
WO2017095808A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
MX2018006477A
(es)
|
2015-12-02 |
2018-09-03 |
Agenus Inc |
Anticuerpos y metodos de uso de estos.
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
CA3004288A1
(en)
|
2015-12-28 |
2017-07-06 |
Nobuyuki Tanaka |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
JP7032662B2
(ja)
|
2015-12-31 |
2022-03-09 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
Pcsk9抗体、その抗原結合フラグメント及び医薬用途
|
WO2017118307A1
(zh)
|
2016-01-05 |
2017-07-13 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
BR112018015659A2
(pt)
|
2016-02-01 |
2018-12-26 |
Bioverativ Therapeutics Inc |
genes otimizados do fator viii
|
TW201730212A
(zh)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
Ror1-結合分子及其使用方法
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
IL307425A
(en)
|
2016-03-04 |
2023-12-01 |
Univ Rockefeller |
CD40 antibodies with increased agonistic activity
|
EA201891990A1
(ru)
|
2016-03-04 |
2019-04-30 |
Шайр Хьюман Дженетик Терапиз, Инк. |
Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
CN109563158B
(zh)
|
2016-04-04 |
2022-08-09 |
比奥贝拉蒂美国公司 |
抗补体因子bb抗体以及其用途
|
MA45473A
(fr)
|
2016-04-04 |
2019-02-13 |
Shire Human Genetic Therapies |
Inhibiteur de c1 estérase conjugué et ses utilisations
|
CA3020864A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
AU2017254674A1
(en)
|
2016-04-21 |
2018-11-01 |
Abbvie Stemcentrx Llc |
Novel anti-BMPR1B antibodies and methods of use
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
JP7148504B2
(ja)
|
2016-06-08 |
2022-10-05 |
ゼンコー,インコーポレイティド |
CD32Bに交差結合した抗CD19抗体を用いたIgG4関連疾患の治療
|
EP3478713B1
(de)
|
2016-06-30 |
2022-05-11 |
Prothena Biosciences Limited |
Zusammensetzungen zur behandlung von amyloidose
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
EP3481393B1
(de)
|
2016-07-05 |
2021-04-14 |
Beigene, Ltd. |
Kombination eines pd-1-antagonisten und eines raf-inhibitors zur behandlung von krebs
|
EP3481864A1
(de)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
CN117330747A
(zh)
|
2016-07-15 |
2024-01-02 |
武田药品工业株式会社 |
用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
|
CN117717604A
(zh)
|
2016-07-19 |
2024-03-19 |
梯瓦制药澳大利亚股份有限公司 |
抗cd47联合治疗
|
MX2019001458A
(es)
|
2016-08-02 |
2019-07-04 |
Visterra Inc |
Polipeptidos modificados y usos de los mismos.
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
SG11201801024XA
(en)
|
2016-08-05 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Therapeutic or preventive compositions for il-8-related diseases
|
US10538579B2
(en)
|
2016-08-15 |
2020-01-21 |
Board Of Regents, The University Of Texas System |
Bispecific pertussis antibodies
|
WO2018035107A2
(en)
*
|
2016-08-15 |
2018-02-22 |
Board Of Regents, The University Of Texas System |
Stabilized pertussis antibodies with extended half-life
|
FI3500299T3
(fi)
|
2016-08-19 |
2024-02-14 |
Beigene Switzerland Gmbh |
Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
|
CN110198729A
(zh)
|
2016-09-09 |
2019-09-03 |
豪夫迈·罗氏有限公司 |
卷曲蛋白的选择性肽抑制剂
|
US20190270821A1
(en)
|
2016-09-13 |
2019-09-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
US10844119B2
(en)
|
2016-10-11 |
2020-11-24 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
KR20190064636A
(ko)
|
2016-10-19 |
2019-06-10 |
메디뮨 엘엘씨 |
항-o1 항체 및 이의 용도
|
TW202300515A
(zh)
|
2016-10-20 |
2023-01-01 |
法商賽諾菲公司 |
抗chikv抗體及其用途
|
AU2017345759A1
(en)
|
2016-10-21 |
2019-05-23 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
CA3040893A1
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
MX2019006446A
(es)
|
2016-12-02 |
2019-12-11 |
Bioverativ Therapeutics Inc |
Métodos para inducir tolerancia inmunológica a factores de coagulación.
|
MA46967A
(fr)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc |
Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
WO2018106781A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc |
Anti-tau antibodies and methods of use
|
IL307242A
(en)
|
2016-12-07 |
2023-11-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
WO2018106776A2
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
AR110414A1
(es)
|
2016-12-21 |
2019-03-27 |
Cephalon Inc |
Anticuerpos que se unen específicamente a il-15 humana y usos de estos
|
AU2017382234A1
(en)
|
2016-12-23 |
2019-07-04 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
TWI783957B
(zh)
|
2016-12-23 |
2022-11-21 |
美商伊繆諾金公司 |
靶向adam9之免疫共軛物及其使用方法
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
JP2020503351A
(ja)
|
2017-01-06 |
2020-01-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
|
IL267990B2
(en)
|
2017-01-25 |
2024-04-01 |
Molecular Templates Inc |
Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
|
EP3574004A1
(de)
|
2017-01-25 |
2019-12-04 |
Medimmune, LLC |
Relaxin-fusionspolypeptide und verwendungen davon
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
US11203636B2
(en)
|
2017-02-01 |
2021-12-21 |
Yale University |
Treatment of existing left ventricular heart failure
|
JP7304288B2
(ja)
|
2017-02-17 |
2023-07-06 |
サノフイ |
ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子
|
RS63818B1
(sr)
|
2017-02-17 |
2023-01-31 |
Denali Therapeutics Inc |
Konstruisani polipeptidi za vezivanje za receptor transferina
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
MX2019009967A
(es)
|
2017-02-24 |
2019-12-02 |
Macrogenics Inc |
Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
|
WO2018157163A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
MA49886A
(fr)
|
2017-03-16 |
2020-06-24 |
Medimmune Ltd |
Anticorps anti-par2 et leurs utilisations
|
UY37651A
(es)
|
2017-03-31 |
2018-10-31 |
Swedish Orphan Biovitrum Ab Publ |
Polipéptido de unión al il-1r-i
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗cd137抗体およびその使用方法
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
WO2018195338A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
HUE062927T2
(hu)
|
2017-05-01 |
2023-12-28 |
Agenus Inc |
Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
MX2019013137A
(es)
|
2017-05-05 |
2020-07-14 |
Allakos Inc |
Metodos y composiciones para tratar enfermedades oculares alergicas.
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
AU2018266893A1
(en)
|
2017-05-12 |
2019-12-05 |
Takeda Pharmaceutical Company Limited |
Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
SI3658184T1
(sl)
|
2017-07-27 |
2024-01-31 |
Alexion Pharmaceuticals, Inc., |
Formulacije z visoko koncentracijo protiteles proti-C5
|
JP7374883B2
(ja)
|
2017-08-09 |
2023-11-07 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子およびその使用
|
MX2020002070A
(es)
|
2017-08-22 |
2020-03-24 |
Sanabio Llc |
Receptores solubles de interferon y usos de los mismos.
|
MA49950A
(fr)
|
2017-08-25 |
2020-07-01 |
Five Prime Therapeutics Inc |
Anticorps anti-b7-h4 et leurs procédés d'utilisation
|
JP7039694B2
(ja)
|
2017-10-31 |
2022-03-22 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
US10538583B2
(en)
|
2017-10-31 |
2020-01-21 |
Staten Biotechnology B.V. |
Anti-APOC3 antibodies and compositions thereof
|
JP7465210B2
(ja)
|
2017-11-29 |
2024-04-10 |
シーエスエル リミティド |
虚血-再灌流障害の治療又は予防方法
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
EP3720877A1
(de)
|
2017-12-08 |
2020-10-14 |
Argenx BVBA |
Verwendung von fcrn-antagonisten zur behandlung von generalisierter myasthenia gravis
|
RU2020122822A
(ru)
|
2017-12-12 |
2022-01-13 |
Макродженикс, Инк. |
Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
FR3076294B1
(fr)
|
2017-12-29 |
2022-01-28 |
Lab Francais Du Fractionnement |
Procede de purification d'anticorps a partir de lait brut
|
CA3087699A1
(en)
|
2018-01-05 |
2019-07-11 |
Corvidia Therapeutics, Inc. |
Methods for treating il-6 mediated inflammation without immunosuppression
|
WO2019139891A1
(en)
|
2018-01-09 |
2019-07-18 |
Synthetic Biologics, Inc. |
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
|
BR112020014052A2
(pt)
|
2018-01-12 |
2020-12-08 |
Takeda Pharmaceutical Company Limited |
Dosagem subcutânea de anticorpos anti-cd38
|
CN111918674A
(zh)
|
2018-02-01 |
2020-11-10 |
比奥维拉迪维治疗股份有限公司 |
表达因子viii的慢病毒载体的用途
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
AU2019222705A1
(en)
|
2018-02-14 |
2020-10-01 |
Horizon Therapeutics Ireland Dac |
Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス,インコーポレーテッド |
変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
WO2019169212A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
WO2019183209A1
(en)
|
2018-03-20 |
2019-09-26 |
Synthetic Biologics, Inc. |
Alkaline phosphatase agents for treatment of radiation disorders
|
WO2019183266A1
(en)
*
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
EP4163295A1
(de)
|
2018-03-23 |
2023-04-12 |
Université Libre de Bruxelles |
Agonistenmoleküle des wnt-signalwegs
|
EA202092316A1
(ru)
|
2018-03-28 |
2021-05-25 |
Бристол-Маерс Сквибб Компани |
Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
|
CA3095086A1
(en)
|
2018-03-28 |
2019-10-03 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-cd38 antibodies
|
ES2955511T3
(es)
|
2018-05-14 |
2023-12-04 |
Werewolf Therapeutics Inc |
Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
|
AU2019271149B2
(en)
|
2018-05-14 |
2023-07-13 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
KR20210013091A
(ko)
|
2018-05-16 |
2021-02-03 |
시에스엘 리미티드 |
가용성 보체 수용체 1형 변이체 및 이의 용도
|
BR112020022164A2
(pt)
|
2018-05-18 |
2021-02-02 |
Bioverativ Therapeutics Inc. |
métodos de tratamento de hemofilia a
|
KR20210027352A
(ko)
|
2018-06-04 |
2021-03-10 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-vla-4 항체
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
WO2019241628A1
(en)
|
2018-06-15 |
2019-12-19 |
Proclara Biosciences, Inc. |
General amyloid interaction motif (gaim)
|
SG11202012257VA
(en)
|
2018-06-26 |
2021-01-28 |
Immunogen Inc |
Immunoconjugates targeting adam9 and methods of use thereof
|
BR112020026512A2
(pt)
|
2018-07-03 |
2021-04-06 |
Bristol-Myers Squibb Company |
Formulações de fgf-21
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3823664A1
(de)
|
2018-07-19 |
2021-05-26 |
Regeneron Pharmaceuticals, Inc. |
Bispezifische anti-bcma-x-nti-cd3-antikörper und ihre verwendungen
|
JP2021533753A
(ja)
|
2018-08-09 |
2021-12-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
CN112771067A
(zh)
|
2018-08-29 |
2021-05-07 |
沙塔克实验室有限公司 |
包含基于SIRPα的嵌合蛋白的组合疗法
|
WO2020047462A2
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
EP3843788A1
(de)
*
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Einkettige chimäre polypeptide und deren verwendungen
|
CN112996805A
(zh)
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
EP3844280A4
(de)
*
|
2018-08-31 |
2022-09-14 |
Yale University |
Enpp1-polypeptide und verfahren zu deren verwendung
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
WO2020069398A1
(en)
|
2018-09-27 |
2020-04-02 |
Akrevia Therapeutics Inc. |
Masked cytokine polypeptides
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
TW202029980A
(zh)
|
2018-10-26 |
2020-08-16 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
WO2020088164A1
(zh)
|
2018-11-01 |
2020-05-07 |
山东新时代药业有限公司 |
双特异性抗体及其用途
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗pd-1抗體呈現難治性之非小細胞肺癌(nsclc)病患之治療
|
EP3876989A4
(de)
|
2018-11-09 |
2022-12-07 |
University of Massachusetts |
Anti-cfae-antikörper und verfahren zur verwendung
|
JP2022509942A
(ja)
|
2018-11-16 |
2022-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗nkg2a抗体およびその使用
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
CN113227134A
(zh)
|
2018-12-05 |
2021-08-06 |
株式会社梅花治疗 |
抗体的Fc区变体
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
TW202039583A
(zh)
|
2018-12-07 |
2020-11-01 |
瑞士商巴克斯歐塔有限公司 |
結合因子IXa及因子X的蛋白分子
|
WO2020114616A1
(en)
|
2018-12-07 |
2020-06-11 |
Tillotts Pharma Ag |
Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
|
WO2020115283A1
(en)
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
SI3723858T1
(sl)
|
2018-12-21 |
2022-04-29 |
Kymab Limited |
Bispecifično protitelo FIXAXFX s skupno lahko verigo
|
KR20210141447A
(ko)
|
2018-12-26 |
2021-11-23 |
실리오 디벨럽먼트, 인크. |
항-ctla4 항체 및 이의 사용 방법
|
JP2022516505A
(ja)
|
2018-12-28 |
2022-02-28 |
スパークス・セラピューティクス・インコーポレイテッド |
癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法
|
CN113597319A
(zh)
|
2019-01-04 |
2021-11-02 |
分解治疗有限责任公司 |
用核酸酶融合蛋白治疗干燥症
|
CN113614107A
(zh)
|
2019-01-23 |
2021-11-05 |
Encefa公司 |
Cd31竞争剂及其用途
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
CA3131654A1
(en)
|
2019-02-26 |
2020-09-03 |
Janssen Biotech, Inc. |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
BR112021016875A2
(pt)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Processo para expansão de linfócitos de sangue periférico
|
CN113811332A
(zh)
|
2019-03-05 |
2021-12-17 |
普罗塞纳生物科学有限公司 |
治疗al淀粉样变性的方法
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
EP3962942A1
(de)
|
2019-05-01 |
2022-03-09 |
Novo Nordisk A/S |
Anti-il-6-antikörperformulierung
|
JP2022532217A
(ja)
|
2019-05-14 |
2022-07-13 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
分離部分及びその使用方法
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
MX2021014756A
(es)
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
|
MX2021015045A
(es)
|
2019-06-07 |
2022-03-17 |
Amgen Inc |
Construcciones de unión biespecíficas.
|
US20220241413A1
(en)
|
2019-06-10 |
2022-08-04 |
Takeda Pharmaceutical Company Limited |
Combination therapies using cd-38 antibodies
|
EP3986918A1
(de)
|
2019-06-18 |
2022-04-27 |
Bayer Aktiengesellschaft |
Adrenomedullin-analoga zur langzeitstabilisierung und ihre verwendung
|
AU2020294797A1
(en)
|
2019-06-21 |
2021-12-23 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
US20230018417A1
(en)
|
2019-07-26 |
2023-01-19 |
Shire Human Genetic Therapies, Inc. |
Recombinant Heme Oxygenase-1 (HO-1) for the Treatment of Sickle Cell Disease
|
CN114502593A
(zh)
|
2019-08-06 |
2022-05-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和相关方法
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
JP2022544785A
(ja)
|
2019-08-13 |
2022-10-21 |
エルピス・バイオファーマシューティカルズ |
改変インターロイキン2受容体ベータアゴニスト
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
EP4038182A1
(de)
|
2019-09-30 |
2022-08-10 |
Bioverativ Therapeutics Inc. |
Lentivirale vektorformulierungen
|
CN114651006A
(zh)
|
2019-11-15 |
2022-06-21 |
恩瑟拉有限责任公司 |
Tmem219抗体及其治疗性用途
|
JP2023503105A
(ja)
|
2019-11-21 |
2023-01-26 |
エンテラ・エッセ・エッレ・エッレ |
Igfbp3抗体及びその治療的使用
|
IL293314A
(en)
|
2019-11-29 |
2022-07-01 |
Kymab Ltd |
Treatment of physiological iron overload
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
US20210236596A1
(en)
|
2020-01-08 |
2021-08-05 |
argenx BV |
Methods for treating pemphigus disorders
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
EP3868396A1
(de)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitoren und verwendungen davon
|
JP2023516952A
(ja)
|
2020-02-28 |
2023-04-21 |
ジェンザイム・コーポレーション |
最適化された薬物コンジュゲーションのための改変された結合ポリペプチド
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
US20230174626A1
(en)
|
2020-03-27 |
2023-06-08 |
Glaxosmithkline Biologicals Sa |
Antibodies
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
AU2021261257A1
(en)
|
2020-04-20 |
2022-12-22 |
Genzyme Corporation |
Humanized anti-complement factor Bb antibodies and uses thereof
|
BR112022021450A2
(pt)
|
2020-04-24 |
2022-12-27 |
Millennium Pharm Inc |
O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
WO2021233834A1
(en)
|
2020-05-17 |
2021-11-25 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
AU2021275499A1
(en)
|
2020-05-22 |
2022-11-24 |
Formycon Ag |
Ace2-fc fusion proteins and uses thereof
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
JPWO2021251438A1
(de)
|
2020-06-10 |
2021-12-16 |
|
|
CA3186143A1
(en)
|
2020-06-17 |
2021-12-23 |
Medimmune Limited |
Heterodimeric relaxin fusions and uses thereof
|
US20230220088A1
(en)
*
|
2020-06-23 |
2023-07-13 |
Maddon Advisors Llc |
Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods
|
EP4169949A1
(de)
|
2020-06-23 |
2023-04-26 |
Jiangsu Kanion Pharmaceutical Co., Ltd. |
Anti-cd38-antikörper und verwendung davon
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP4175650A1
(de)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon
|
AR122933A1
(es)
|
2020-07-10 |
2022-10-19 |
Novo Nordisk As |
Métodos para tratar la enfermedad cardiovascular
|
JP2023536904A
(ja)
|
2020-08-06 |
2023-08-30 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労
|
WO2022034044A1
(en)
|
2020-08-10 |
2022-02-17 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies for treatment and prevention of covid-19
|
MX2023002001A
(es)
|
2020-08-18 |
2023-03-21 |
Cephalon Llc |
Anticuerpos anti-par-2 y metodos de uso de los mismos.
|
US20230340054A1
(en)
|
2020-09-01 |
2023-10-26 |
Takeda Pharmaceutical Company Limited |
Interleukin-2 muteins and uses thereof
|
AR123480A1
(es)
|
2020-09-11 |
2022-12-07 |
Medimmune Ltd |
Moléculas de unión terapéuticas
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
KR20230124550A
(ko)
*
|
2020-10-14 |
2023-08-25 |
비리디안 쎄라퓨틱스, 인크. |
갑상선 눈 질환의 치료를 위한 조성물 및 방법
|
MX2023004933A
(es)
|
2020-10-29 |
2023-06-06 |
Formycon Ag |
Proteinas de fusion de ace2 y usos de las mismas.
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
EP4255574A1
(de)
|
2020-12-01 |
2023-10-11 |
Aptevo Research and Development LLC |
Heterodimere psma- und cd3-bindende bispezifische antikörper
|
CA3203468A1
(en)
|
2020-12-03 |
2022-06-09 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
AU2021397734A1
(en)
*
|
2020-12-08 |
2023-07-06 |
Janux Therapeutics, Inc. |
Half-life extending compositions and methods
|
JP2023552812A
(ja)
|
2020-12-09 |
2023-12-19 |
ジャナックス セラピューティクス,インク. |
Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
EP4262827A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebs mit tumorinfiltrierenden lymphozyten
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
US20240059763A1
(en)
|
2020-12-18 |
2024-02-22 |
Zhuhai Trinomab Pharmaceutical Co., Ltd. |
Respiratory syncytial virus-specific binding molecule
|
JP2024501845A
(ja)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
KR20230148169A
(ko)
|
2021-01-22 |
2023-10-24 |
엘피스 바이오파마슈티컬즈 |
항-pd-l1 모노클로날 항체 및 인터루킨-15 (il-15), 인터루킨-15 수용체 15 알파 또는 인터루킨-2와의 융합 단백질
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
JP2024509543A
(ja)
|
2021-03-03 |
2024-03-04 |
フォーマイコン アーゲー |
ACE2 Fc融合タンパク質の製剤
|
CA3210755A1
(en)
|
2021-03-05 |
2022-09-09 |
Kenneth ONIMUS |
Tumor storage and cell culture compositions
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4313122A1
(de)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish-geneditierung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
|
EP4314253A2
(de)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
JP2024513837A
(ja)
|
2021-03-31 |
2024-03-27 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
寒冷凝集素症患者における手術関連溶血の低減
|
IL307382A
(en)
|
2021-03-31 |
2023-11-01 |
Cambridge Entpr Ltd |
Therapeutic inhibitors of GDF15 signaling
|
WO2022207785A1
(en)
|
2021-03-31 |
2022-10-06 |
Kymab Limited |
Antibodies to gfral
|
CN117425673A
(zh)
|
2021-04-09 |
2024-01-19 |
武田药品工业株式会社 |
靶向补体因子d的抗体和其用途
|
BR112023021665A2
(pt)
|
2021-04-19 |
2023-12-19 |
Iovance Biotherapeutics Inc |
Método para tratar um câncer, e, composição
|
CA3216770A1
(en)
|
2021-04-26 |
2022-11-03 |
Tomoki Yoshihara |
Anti-clec12a antibodies and uses thereof
|
CN117580860A
(zh)
|
2021-04-26 |
2024-02-20 |
米伦纽姆医药公司 |
抗adgre2抗体及其用途
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
BR112023024804A2
(pt)
|
2021-05-28 |
2024-02-15 |
Glaxosmithkline Ip Dev Ltd |
Terapias de combinação para tratar câncer
|
EP4348260A2
(de)
|
2021-06-03 |
2024-04-10 |
Scholar Rock, Inc. |
Tgf-beta inhibitoren und deren therapeutische verwendung
|
AU2022293999A1
(en)
|
2021-06-14 |
2023-11-30 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
AU2022299185A1
(en)
|
2021-06-23 |
2024-01-25 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
KR20240040786A
(ko)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
|
WO2023023503A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Yale University |
Interleukin-12 variants and methods of use
|
CA3227716A1
(en)
|
2021-08-20 |
2023-02-23 |
Intervet International B.V. |
Antibodies and igg fusion proteins with an extended half-life
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
CN117881784A
(zh)
|
2021-08-31 |
2024-04-12 |
大正制药株式会社 |
抗生长激素抗体
|
WO2023039488A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CA3232806A1
(en)
|
2021-09-30 |
2023-04-06 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
WO2023094507A1
(en)
|
2021-11-24 |
2023-06-01 |
Formycon Ag |
Improved ace2 fusion proteins
|
WO2023094571A1
(en)
|
2021-11-25 |
2023-06-01 |
Formycon Ag |
Stabilization of ace2 fusion proteins
|
WO2023111112A1
(en)
|
2021-12-15 |
2023-06-22 |
Medimmune Limited |
Treatment using heterodimeric relaxin fusions
|
WO2023114951A1
(en)
|
2021-12-17 |
2023-06-22 |
Viiv Healthcare Company |
Combination therapies for hiv infections and uses thereof
|
WO2023139107A1
(en)
|
2022-01-18 |
2023-07-27 |
argenx BV |
Galectin-10 antibodies
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023168352A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
US20230348604A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
KR20230156844A
(ko)
|
2022-05-02 |
2023-11-14 |
노보 노르디스크 에이/에스 |
고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023220597A1
(en)
|
2022-05-10 |
2023-11-16 |
Elpis Biopharmaceuticals |
Engineered interleukin-2 receptor beta reduced-binding agonist
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023242361A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn binding molecules and methods of use
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024015830A1
(en)
|
2022-07-12 |
2024-01-18 |
Cytomx Therapeutics, Inc. |
Epcam immunoconjugates and uses thereof
|
US20240034780A1
(en)
|
2022-07-22 |
2024-02-01 |
Flagship Pioneering Innovations Vi, Llc |
Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)
|
WO2024026386A1
(en)
|
2022-07-27 |
2024-02-01 |
Cephalon Llc |
Anti-tl1a antibody formulations
|
WO2024026395A1
(en)
|
2022-07-27 |
2024-02-01 |
Cephalon Llc |
Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024026470A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024050421A2
(en)
|
2022-08-30 |
2024-03-07 |
Flagship Pioneering Innovations Vi, Llc |
Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
|
US20240101691A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|